Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About GYRE Interactive Breakdown Better Bets vs. GYRE Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Gyre Therapeutics (GYRE)

Market Price (10/31/2025): $7.67 | Market Cap: $683.5 Mil
Sector: Health Care | Industry: Biotechnology

Gyre Therapeutics (GYRE)

Market Price (10/31/2025): $7.67
Market Cap: $683.5 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35%		 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 15		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 73x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 735x, P/EPrice/Earnings or Price/(Net Income) is 164x
1   Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -8.4%
2   Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.6%
3   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.9%
0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35%
1 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 15
2 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 73x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 735x, P/EPrice/Earnings or Price/(Net Income) is 164x
3 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -8.4%
4 Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.6%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.9%

Market Valuation & Key Metrics

GYRES&P 500
REVENUE GROWTHVERY POOR
Rev LTM ($ Bil)0.1
Rev Chg Q6.1%6.4%
Rev Chg LTM-8.4%5.4%
Rev Chg 3Y Avg-8.4%5.3%
PROFITABILITYVERY POOR
Op Inc LTM ($ Bil)0.0
CFO LTM ($ Bil)0.0
Net Inc LTM ($ Bil)0.0
Op Mgn LTM9.1%18.7%
CFO/Rev LTM0.9%20.4%
Net Inc Mgn4.1%12.8%
VALUATIONHIGH
P/S6.73.2
P/CFO737.415.5
P/FCF-423.520.6
P/E164.123.6
STABILITYVERY GOOD
Debt/Equity0.000.21
Cash/Assets0.360.07

GYRE Stock

   
   
   
   
   
   
   
Factor Drivers of Stock Movement
The -18.1% change in GYRE stock from 5/1/2025 to 10/30/2025 was primarily driven by a -64.3% change in the company's Net Income Margin (%).

501202510302025Change
Stock Price ($)9.347.65-18.09%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)105.76102.19-3.37%
Net Income Margin (%)11.43%4.08%-64.33%
P/E Multiple66.43163.69146.39%
Shares Outstanding (Mil)85.9689.12-3.68%
Cumulative Contribution-18.20%

LTM = Last Twelve Months as of date shown
The -48.0% change in GYRE stock from 10/30/2024 to 10/30/2025 was primarily driven by a -16.4% change in the company's Shares Outstanding (Mil).

1030202410302025Change
Stock Price ($)14.717.65-47.99%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)�102.19�
Net Income Margin (%)�4.08%�
P/E Multiple�163.69�
Shares Outstanding (Mil)76.5889.12-16.37%
Cumulative Contribution�

LTM = Last Twelve Months as of date shown
null

null

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
GYRE Return-7%-86%120%4770%-53%-37%356%
Peers Return-15%-9%-6%-3%-3%-16%-43%
S&P 500 Return16%27%-19%24%23%16%110%

Monthly Win Rates [3]
GYRE Win Rate58%25%58%75%33%33% 
Peers Win Rate18%15%23%31%22%51% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
GYRE Max Drawdown-49%-86%-61%-64%-64%-47% 
Peers Max Drawdown-20%-13%-14%-15%-30%-27% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique KeyEventGYRES&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-95.0%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven1885.0%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven542 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-58.9%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven143.1%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven1330 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-87.3%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven687.6%24.7%
2018 CorrectionTime to BreakevenTime to BreakevenNot Fully Recovered days120 days

Compare to VRTX, APM, BBOT, GDTC, HIND


In The Past

Gyre Therapeutics's stock fell -95.0% during the 2022 Inflation Shock from a high on 2/17/2021. A -95.0% loss requires a 1885.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Gyre Therapeutics (GYRE)

Better Bets than Gyre Therapeutics (GYRE)

 GYREBetter Performance than GYRE
MetricValueIndustry (Biotechnology)
Rev Chg LTM-8.4%ABBV (6.1%), AMGN (12.9%), GILD (3.8%), VRTX (10.5%), REGN (2.9%)
Op Mgn LTM9.1%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), REGN (26.7%), BIIB (24.8%)
CFO/Rev LTM0.9%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (35.6%)
FCF/Rev LTM-1.6%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (27.2%)
Total Yield0.6%ABBV (3.7%), AMGN (7.4%), GILD (7.0%), VRTX (3.4%), REGN (7.2%)
 GYREBetter Performance than GYRE
MetricValueAll Other Sectors
Rev Chg LTM-8.4%NVDA (71.6%), AAPL (6.0%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%)
Op Mgn LTM9.1%NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM0.9%NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM-1.6%NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield0.6%NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)
 Best Bets In Health Care Sector
 GYRERPRX HALO CPRX BMY LNTH PBH BIIB PFE EW ILMN
What You Pay           
P/E163.715.314.112.315.414.014.013.612.811.812.4
P/EBIT73.08.111.010.59.39.69.010.110.329.210.3
What You Get           
Rev Chg Q6.1%7.7%40.8%19.4%2.8%-4.1%-6.6%2.8%10.3%11.9%-4.8%
Rev Chg LTM-8.4%3.0%35.0%28.5%1.3%5.7%0.6%4.8%13.5%9.1%-3.3%
Rev Chg 3Y Avg�0.8%35.5%49.9%1.0%34.3%0.8%-0.9%-12.4%3.0%-3.0%
FCF/Rev 3Y Avg�113.4%43.4%38.9%29.0%26.1%21.6%17.0%13.8%11.9%9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

Trade Ideas

Select past ideas related to GYRE. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PRAXPraxis Precision Medicines279.1%161.2%
2INBXInhibrx Biosciences131.0%409.8%
3PUMPProPetro99.6%16.2%
4DYNDyne Therapeutics88.4%-0.0%
5VICRVicor85.4%89.2%
6CELCCelcuity74.6%503.2%
7GLUEMonte Rosa Therapeutics73.5%87.5%
8NVTSNavitas Semiconductor72.1%251.8%
9LUMNLumen Technologies70.3%94.7%
10BALYBallys63.4%4.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical-62.9%5106.3%
2LRNStride-53.8%-35.8%
3FMCFMC-51.0%-66.6%
4FIFiserv-48.3%-68.3%
5NFENew Fortress Energy-43.6%-91.9%
6VGVenture Global-41.7% 
7OGNOrganon-40.2%-55.0%
8VRNSVaronis Systems-39.5%-21.2%
9ITGRInteger-38.5%-52.2%
10LENZLENZ Therapeutics-37.9%5.5%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Gyre Therapeutics

Financials

GYREVRTXAPMBBOTGDTCHINDMedian
NameGyre The.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Mkt Price7.65419.891.4712.002.155.586.62
Mkt Cap0.7107.8----54.2
Rev LTM10211,419-0--102
Op Inc LTM9-199--93---93
FCF LTM-23,500--60---2
FCF 3Y Avg-1,984----1,984
CFO LTM13,846--60--1
CFO 3Y Avg-2,324----2,324

Growth & Margins

GYREVRTXAPMBBOTGDTCHINDMedian
NameGyre The.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Rev Chg LTM-8.4%10.5%----1.0%
Rev Chg 3Y Avg-11.0%----11.0%
Rev Chg Q6.1%12.1%----9.1%
QoQ Delta Rev Chg LTM1.5%2.9%----2.2%
Op Mgn LTM9.1%-1.7%----3.7%
Op Mgn 3Y Avg-26.5%----26.5%
QoQ Delta Op Mgn LTM-1.2%2.0%----0.4%
CFO/Rev LTM0.9%33.7%----17.3%
CFO/Rev 3Y Avg-22.5%----22.5%
FCF/Rev LTM-1.6%30.6%----14.5%
FCF/Rev 3Y Avg-19.2%----19.2%

Valuation

GYREVRTXAPMBBOTGDTCHINDMedian
NameGyre The.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Mkt Cap0.7107.8----54.2
P/S6.79.4----8.1
P/EBIT73.024.5----48.8
P/E163.729.6----96.7
P/CFO735.528.0----381.7
Total Yield0.6%3.4%----2.0%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-2.1%----2.1%
D/E0.00.0----0.0
Net D/E-0.1-0.0-----0.1

Returns

GYREVRTXAPMBBOTGDTCHINDMedian
NameGyre The.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
1M Rtn2.5%7.2%-27.2%3.6%8.0%7.7%5.4%
3M Rtn8.5%-8.1%-5.2%-14.4%-1.7%
6M Rtn-18.1%-15.8%59.8%--6.5%--11.2%
12M Rtn-48.0%-11.6%5.0%--3.4%--7.5%
3Y Rtn1,316.4%34.6%-76.8%---34.6%
1M Excs Rtn-0.7%2.2%-34.2%-1.9%5.3%-0.2%-0.5%
3M Excs Rtn5.7%-18.5%-2.1%-8.1%-1.8%
6M Excs Rtn-39.8%-37.6%38.0%--28.3%--32.9%
12M Excs Rtn-64.0%-29.0%-17.8%--33.2%--31.1%
3Y Excs Rtn1,124.0%-41.0%-151.9%----41.0%

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q1
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/20233/31/2022
Filing Date8/11/20255/9/20253/17/202511/13/20248/13/20245/13/20243/27/202411/13/20248/13/20247/20/20237/20/2023
Key Financials Quarterly           
Total Revenue2722282525272732292525
Ebitda331538-513578
Operating Income221438-513578
Net Income03-0148-1014226
EPS0.000.030.000.010.040.09-1.320.050.020.030.08
Key Financials TTM           
Total Revenue TTM102101106105112116113111---
Ebitda TTM1112181220222034---
Operating Income TTM910161019211932---
Net Income TTM4712-89-86-88-9314---
Growth Rates Quarterly           
Total Revenue Growth6.1%-18.8%2.7%-20.5%-14.0%9.0%8.5%----
EBITDA Growth-19.4%-66.9%123.2%-63.7%-34.1%22.1%-157.9%----
Operating Income Growth-33.4%-71.8%112.8%-66.8%-34.4%21.1%-165.0%----
Net Income Growth-87.5%-64.2%99.9%-71.7%90.4%235.7%-1741.9%----
Margins Quarterly           
EBITDA Margin10.5%12.7%4.1%18.5%13.8%31.2%-18.0%40.5%18.0%27.9%33.7%
Operating Income Margin8.1%10.3%2.4%16.6%12.9%29.7%-19.1%39.8%17.0%26.7%31.9%
Net Income Margin1.7%12.2%-0.4%4.4%14.0%27.7%-372.1%12.4%6.3%9.0%24.6%
Cash & Debt           
Total Cash54302725253734--27-
Total Debt12222000010
Net Debt / (Cash)-53-28-25-23-23-37-33---26-
Cash Flows Quarterly           
FCF from Operations2-0-32-53385109
Cash Flows TTM           
FCF from Operations TTM1-7-428182632---
Returns to Shareholders Quarterly           
Dividends00000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly           
ROIC5.6%6.6%1.7%10.9%8.8%26.3%-56.7%--76.6%-
Return on Invested Capital (ROIC) TTM           
ROIC TTM6.4%7.2%11.2%9.2%16.9%21.1%52.5%----

Price Behavior

GYRE Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta0.743.263.471.381.331.90
Up Beta-5.013.133.141.141.160.59
Down Beta-2.752.793.830.781.001.43
Up Capture102%324%319%255%151%1035%
Bmk +ve Days13233574144420
Stock +ve Days9202962127370
Down Capture352%365%387%205%147%103%
Bmk -ve Days8192952107330
Stock -ve Days12223463122370

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity1,502,320
Short Interest: % Change Since 9302025-10.1%
Average Daily Volume100,600
Days-to-Cover Short Interest14.93
Basic Shares Quantity89,119,344
Short % of Basic Shares1.7%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/11/20256.9%11.0%15.6%
5/9/202513.6%19.1%-5.6%
2/18/20256.0%-11.9%-28.5%
11/13/2024-9.6%-19.3%-38.9%
8/13/2024-2.5%10.2%29.2%
5/9/2024-2.7%0.4%-26.3%
2/14/20248.1%8.3%13.5%
8/14/20234.0%61.6%44.2%
...
SUMMARY STATS   
# Positive9118
# Negative10811
Median Positive4.5%8.3%14.6%
Median Negative-2.9%-9.5%-26.0%
Max Positive13.6%61.6%44.2%
Max Negative-41.8%-54.4%-63.6%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025811202510-Q 6/30/2025
3312025509202510-Q 3/31/2025
12312024317202510-K 12/31/2024
93020241113202410-Q 9/30/2024
6302024813202410-Q 6/30/2024
3312024513202410-Q 3/31/2024
12312023327202410-K 12/31/2023
123120227202023DEFM14A 12/31/2022

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Ma SongjiangPresident5292025Sell10.282,00020,56028,852,280Form
1Ma SongjiangPresident5272025Sell10.972,00021,94030,812,799Form
2Ma SongjiangPresident5222025Sell11.252,00022,50031,644,270Form
3Ma SongjiangPresident5202025Sell11.312,00022,62031,858,279Form
4Ma SongjiangPresident5162025Sell11.302022631,875,311Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.